Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 92Breast Neoplasms 69Prostatic Neoplasms 33Triple Negative Breast Neoplasms 32Neoplasms 26Fallopian Tube Neoplasms 25Neoplasm Metastasis 21Endometrial Neoplasms 19Pancreatic Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

Hyperthermic Intraperitoneal Chemotherapy 28Paclitaxel 24Cisplatin 23Oxaliplatin 18Cytoreduction Surgical Procedures 17Carboplatin 17Fluorouracil 14Bevacizumab 10Mitomycin 9Leucovorin 9Doxorubicin 9Docetaxel 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Neoadjuvant Therapy 4Blood Specimen Collection 4Albumin-Bound Paclitaxel 4sodium thiosulfate 3liposomal doxorubicin 3catumaxomab 3Taxes 3Laparoscopy 3Drug Therapy 3Chemotherapy, Adjuvant 3tremelimumab 2relacorilant 2pembrolizumab 2olaparib 2nintedanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × olaparib × Clear all
NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

New Mexico Cancer Research Alliance

Phase 1/2 Active not recruiting
50 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡